These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 18768802)

  • 1. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.
    Masri B; Salahpour A; Didriksen M; Ghisi V; Beaulieu JM; Gainetdinov RR; Caron MG
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13656-61. PubMed ID: 18768802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.
    Klewe IV; Nielsen SM; Tarpø L; Urizar E; Dipace C; Javitch JA; Gether U; Egebjerg J; Christensen KV
    Neuropharmacology; 2008 Jun; 54(8):1215-22. PubMed ID: 18455202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.
    Allen JA; Yost JM; Setola V; Chen X; Sassano MF; Chen M; Peterson S; Yadav PN; Huang XP; Feng B; Jensen NH; Che X; Bai X; Frye SV; Wetsel WC; Caron MG; Javitch JA; Roth BL; Jin J
    Proc Natl Acad Sci U S A; 2011 Nov; 108(45):18488-93. PubMed ID: 22025698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.
    Free RB; Chun LS; Moritz AE; Miller BN; Doyle TB; Conroy JL; Padron A; Meade JA; Xiao J; Hu X; Dulcey AE; Han Y; Duan L; Titus S; Bryant-Genevier M; Barnaeva E; Ferrer M; Javitch JA; Beuming T; Shi L; Southall NT; Marugan JJ; Sibley DR
    Mol Pharmacol; 2014 Jul; 86(1):96-105. PubMed ID: 24755247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.
    Deslauriers J; Desmarais C; Sarret P; Grignon S
    J Mol Neurosci; 2013 May; 50(1):134-45. PubMed ID: 22975849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative Bioluminescence Resonance Energy Transfer Assay Reveals Differential Agonist-Induced D2 Receptor Intracellular Trafficking and Arrestin-3 Recruitment.
    De Vries L; Finana F; Cathala C; Ronsin B; Cussac D
    Mol Pharmacol; 2019 Sep; 96(3):308-319. PubMed ID: 31266815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-Like Efficacy of Dopamine D
    Sahlholm K; Gómez-Soler M; Valle-León M; López-Cano M; Taura JJ; Ciruela F; Fernández-Dueñas V
    Mol Neurobiol; 2018 Jun; 55(6):4952-4958. PubMed ID: 28779351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor.
    Peterson SM; Pack TF; Wilkins AD; Urs NM; Urban DJ; Bass CE; Lichtarge O; Caron MG
    Proc Natl Acad Sci U S A; 2015 Jun; 112(22):7097-102. PubMed ID: 25964346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment.
    Weïwer M; Xu Q; Gale JP; Lewis M; Campbell AJ; Schroeder FA; Van de Bittner GC; Walk M; Amaya A; Su P; D Ordevic L; Sacher JR; Skepner A; Fei D; Dennehy K; Nguyen S; Faloon PW; Perez J; Cottrell JR; Liu F; Palmer M; Pan JQ; Hooker JM; Zhang YL; Scolnick E; Wagner FF; Holson EB
    ACS Chem Biol; 2018 Apr; 13(4):1038-1047. PubMed ID: 29485852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor, Ligand and Transducer Contributions to Dopamine D2 Receptor Functional Selectivity.
    Peterson SM; Pack TF; Caron MG
    PLoS One; 2015; 10(10):e0141637. PubMed ID: 26516769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGS2 modulates the activity and internalization of dopamine D2 receptors in neuroblastoma N2A cells.
    Luessen DJ; Hinshaw TP; Sun H; Howlett AC; Marrs G; McCool BA; Chen R
    Neuropharmacology; 2016 Nov; 110(Pt A):297-307. PubMed ID: 27528587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.
    Urs NM; Gee SM; Pack TF; McCorvy JD; Evron T; Snyder JC; Yang X; Rodriguiz RM; Borrelli E; Wetsel WC; Jin J; Roth BL; O'Donnell P; Caron MG
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8178-E8186. PubMed ID: 27911814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
    Urs NM; Snyder JC; Jacobsen JP; Peterson SM; Caron MG
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20732-7. PubMed ID: 23188793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor.
    Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM
    Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers.
    Harmeier A; Obermueller S; Meyer CA; Revel FG; Buchy D; Chaboz S; Dernick G; Wettstein JG; Iglesias A; Rolink A; Bettler B; Hoener MC
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2049-61. PubMed ID: 26372541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D(2) and D(3) receptors.
    Jin M; Min C; Zheng M; Cho DI; Cheong SJ; Kurose H; Kim KM
    Pharmacol Res; 2013 Jan; 67(1):31-41. PubMed ID: 23059541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions.
    Gao Y; Peterson S; Masri B; Hougland MT; Adham N; Gyertyán I; Kiss B; Caron MG; El-Mallakh RS
    Pharmacol Res Perspect; 2015 Feb; 3(1):e00073. PubMed ID: 25692006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
    Conroy JL; Free RB; Sibley DR
    ACS Chem Neurosci; 2015 Apr; 6(4):681-92. PubMed ID: 25660762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.
    Meade JA; Free RB; Miller NR; Chun LS; Doyle TB; Moritz AE; Conroy JL; Watts VJ; Sibley DR
    Psychopharmacology (Berl); 2015 Mar; 232(5):917-30. PubMed ID: 25231919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.